Key developments in "reverse payment" dispute: the Supreme Court agrees to weigh in, and a NJ court refuses to condemn exclusive authorized generics

This past week saw two key developments in the legal dispute over patent settlements including so-called “reverse payments.” First, the Supreme Court agreed to review an Eleventh Circuit decision dismissing a case brought by the Federal Trade Commission (FTC) challenging a patent settlement. Second, a district court in New Jersey issued the first decision to consider the legal treatment of a commitment by a brand name manufacturer to a generic company not to license any other generic companies the right to sell an authorized generic.

Read: "Key developments in "reverse payment" dispute: the Supreme Court agrees to weigh in, and a NJ court refuses to condemn exclusive authorized generics"


Download PDF Share Back To Listing
Loading data